Follow-The-Filings

Security · featured owners

GANX Gain Therapeutics Inc.

COM Equity as of 2026 Q2 among managers we track

  • 1 Owner
  • Max 0.0%
  • $1M

Who owns this now

Largest portfolio weights among featured holders · max 0.0% (David Einhorn - DME Capit...) · not free-float ownership

  1. David Einhorn 0.03%

holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

history
David Einhorn - DME Capital Management 2026 Q2 0.03% Hold 566,130 $1M history

1 current · options excluded

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $55,180 — —
Gross profit — — —
Gross margin — — —
Net income -$22.27M -$20.41M -$20.16M
Net margin * -40354.3% — —

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $17.78M $11.6M $22.24M
Total non-current assets $830,463 $521,406 $581,837
Total assets $18.61M $12.12M $22.82M
Total current liabilities $4.95M $3.91M $3.35M
Total non-current liabilities $1.08M $872,989 $901,831
Total equity $12.58M $7.34M $18.56M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$18.87M -$18.87M -$18.47M
Cash from investing $10.22M $4.98M —
Cash from financing $12.64M $13.01M $28.45M
Net change in cash $4.49M -$1.41M $10.46M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders